86 related articles for article (PubMed ID: 21530195)
1. Thyroxine dosing after I131Radioiodine ablation for differentiated thyroid cancer.
Clarke K; Gill V; Gerrard G
Clin Oncol (R Coll Radiol); 2011 Oct; 23(8):559-60. PubMed ID: 21530195
[No Abstract] [Full Text] [Related]
2. [Evaluation of effects of L-thyroxine therapy in differentiated thyroid carcinoma on the cardiovascular system --prospective study].
Matuszewska G; Roskosz J; Włoch J; Jurecka-Tuleja B; Hasse-Lazar K; Kowalczyk P; Jarzab B
Wiad Lek; 2001; 54 Suppl 1():373-7. PubMed ID: 12182052
[TBL] [Abstract][Full Text] [Related]
3. [Radioiodine therapy of differentiated thyroid cancer. Recommendations of the Therapy Study Group of the German Society of Nuclear Medicine].
Georgi P; Emrich D; Heidenreich P; Moser E; Reiners C; Schicha H
Nuklearmedizin; 1992 Aug; 31(4):151-3. PubMed ID: 1518724
[No Abstract] [Full Text] [Related]
4. Differentiated thyroid carcinoma (DTC) in the elderly: disease outcome, therapeutic approach, and long-term results in a group of 314 patients.
Girelli ME; Casara D; Rubello D; Mazzarotto R; Saladini G; Busnardo B
J Endocrinol Invest; 1999; 22(10 Suppl):45-6. PubMed ID: 10727040
[No Abstract] [Full Text] [Related]
5. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal.
Hänscheid H; Lassmann M; Luster M; Thomas SR; Pacini F; Ceccarelli C; Ladenson PW; Wahl RL; Schlumberger M; Ricard M; Driedger A; Kloos RT; Sherman SI; Haugen BR; Carriere V; Corone C; Reiners C
J Nucl Med; 2006 Apr; 47(4):648-54. PubMed ID: 16595499
[TBL] [Abstract][Full Text] [Related]
6. [Differentiated thyroid cancers].
Gorgone S; Campennì A; Calbo E; Catalfamo A; Sciglitano P; Sofia L; Niceta M; Borzì R; Calbo L
G Chir; 2009; 30(1-2):26-9. PubMed ID: 19272228
[TBL] [Abstract][Full Text] [Related]
7. rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review.
Luster M; Lippi F; Jarzab B; Perros P; Lassmann M; Reiners C; Pacini F
Endocr Relat Cancer; 2005 Mar; 12(1):49-64. PubMed ID: 15788638
[TBL] [Abstract][Full Text] [Related]
8. [Follow-up of papillary and follicular thyroid cancer--when and where?].
Mäenpää HO; Välimäki MJ
Duodecim; 2010; 126(20):2424-30. PubMed ID: 21125756
[TBL] [Abstract][Full Text] [Related]
9. Approach to the patient with advanced differentiated thyroid cancer.
Schlumberger M; Sherman SI
Eur J Endocrinol; 2012 Jan; 166(1):5-11. PubMed ID: 21890651
[TBL] [Abstract][Full Text] [Related]
10. Postoperative management of differentiated thyroid cancer.
Sabet A; Kim M
Otolaryngol Clin North Am; 2010 Apr; 43(2):329-51, viii-ix. PubMed ID: 20510717
[TBL] [Abstract][Full Text] [Related]
11. Urinary iodine in patients with differentiated thyroid cancer (DTC) during L-thyroxine treatment.
Michalik B; Roskosz J; Stanjek-Cichoracka A; Krajewska J; Kalemba M; Kochańska-Dziurowicz A; Jarząb B
Endokrynol Pol; 2010; 61(5):458-61. PubMed ID: 21049458
[TBL] [Abstract][Full Text] [Related]
12. Treatment of thyroid cancer.
Blahd WH
Compr Ther; 1985 Sep; 11(9):26-32. PubMed ID: 4042593
[No Abstract] [Full Text] [Related]
13. Role of 131I in the treatment of well differentiated thyroid cancer.
Woodrum DT; Gauger PG
J Surg Oncol; 2005 Mar; 89(3):114-21. PubMed ID: 15719384
[TBL] [Abstract][Full Text] [Related]
14. Comparison of efficacy of 2220 MBq versus 3700 MBq I-131 for ablation of thyroid remnant in patients with differentiated thyroid cancer.
Fish SA; Basu S; Alavi A; Mandel SJ
Q J Nucl Med Mol Imaging; 2010 Oct; 54(5):560-3. PubMed ID: 20927023
[TBL] [Abstract][Full Text] [Related]
15. Coming of age: recombinant human thyroid-stimulating hormone as a preparation for (131)i therapy in thyroid cancer.
Robbins RJ; Pentlow KS
J Nucl Med; 2003 Jul; 44(7):1069-71. PubMed ID: 12843222
[No Abstract] [Full Text] [Related]
16. Presentation and practical management to optimize radioiodine treatment of well differentiated thyroid cancer: ablation of thyroid remnants with radioiodine.
Janisch A; Altenbrunn HJ; Markwardt J
Radiobiol Radiother (Berl); 1987; 28(5):707-10. PubMed ID: 3441634
[No Abstract] [Full Text] [Related]
17. Iodine 131 ((131)I) as adjuvant therapy of differentiated thyroid cancer.
Lamonica D
Surg Oncol Clin N Am; 2004 Jan; 13(1):129-49. PubMed ID: 15062366
[TBL] [Abstract][Full Text] [Related]
18. New approaches in the management of radioiodine-refractory thyroid cancer: the molecular targeted therapy era.
Capdevila J; Argiles G; Rodriguez-Frexinos V; Nuñez I; Tabernero J
Discov Med; 2010 Feb; 9(45):153-62. PubMed ID: 20193642
[TBL] [Abstract][Full Text] [Related]
19. [Age of menopause in patients with differentiated thyroid cancer treated with radioiodine].
Manuel García-Quirós Muñoz J; Martín Hernández T; Torres Cuadro A; Cambil Molina T; Castro Montaño J; Sendón Pérez A
Endocrinol Nutr; 2010 Mar; 57(3):105-9. PubMed ID: 20304710
[TBL] [Abstract][Full Text] [Related]
20. Thyroid cancer guidelines--what's new?
Gerrard G; Gill V
Clin Oncol (R Coll Radiol); 2008 Apr; 20(3):264-6. PubMed ID: 18343311
[No Abstract] [Full Text] [Related]
[Next] [New Search]
